Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PSTV - PLUS THERAPEUTICS, INC.

IEX Last Trade
1.06
0   0%

Share volume: 300
Last Updated: Thu 26 Dec 2024 06:37:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.06
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 43%
Dept financing 25%
Liquidity 24%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.93%
1 Month
-15.63%
3 Months
-29.87%
6 Months
-26.53%
1 Year
-43.16%
2 Year
248.39%
Key data
Stock price
$1.06
P/E Ratio 
-0.64
DAY RANGE
$1.06 - $1.06
EPS 
-$2.32
52 WEEK RANGE
$1.10 - $2.67
52 WEEK CHANGE
-$36.47
MARKET CAP 
8.432 M
YIELD 
N/A
SHARES OUTSTANDING 
5.896 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/29/2024
BETA 
1.21
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$87,940
AVERAGE 30 VOLUME 
$63,546
Company detail
CEO: Marc H. Hedrick
Region: US
Website: plustherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Plus Therapeutics, Inc. focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma.

Recent news